Press Releases

Press Releases

or

June 18, 2020
CAMBRIDGE, Mass. and BEIJING, China , June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today
June 3, 2020
First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma BEIJING, China and CAMBRIDGE, Mass. , June 03, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company
May 29, 2020
- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR rate - Three-year data from Phase 1/2 trial evaluating patients with WM receiving zanubrutinib treatment
May 29, 2020
Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpoint Company to host investor conference call and webcast on ASCO clinical updates on Friday, May 29 at 8:00 p.m. ET CAMBRIDGE, Mass. and BEIJING, China , May 29, 2020 (GLOBE NEWSWIRE) -- BeiGene,